Relay Therapeutics (RLAY) EBITDA Margin (2021 - 2026)
Relay Therapeutics (RLAY) recorded EBITDA Margin of -25846.86% in Q2 2026, down 14643.76 percentage points from -11203.10% a year earlier and down 23243.99 percentage points from the prior quarter.
Powered by 
Analysis
Relay Therapeutics (RLAY) EBITDA Margin (2021 - 2026) Analysis & Trends
On a TTM basis, Relay Therapeutics' EBITDA Margin came in at -2978.01% as of Jun 30, 2026, up 1068.82 percentage points year-over-year; for FY2025, it was -1948.43%, up 1719.05 percentage points from FY2024.
- Annual EBITDA Margin has a five-year change of -1885.22 percentage points (FY2020 to FY2025).
- Across earlier years, EBITDA Margin came in at -3667.47% in FY2024 (-2227.99 pp), -1439.49% in FY2023 (+19932.35 pp), -21371.83% in FY2022 (-9461.20 pp) and -11910.63% in FY2021 (-11847.42 pp).
- The Q2 2026 figure is the lowest quarterly EBITDA Margin since Q2 2023.
- Peak year-over-year performance for EBITDA Margin in the last five years was a gain of 43349.88 percentage points in Q1 2024, against a drop of 66940.47 percentage points in Q2 2023 at the low end.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | Relay Therapeutics | 3.87 Bn | 3.87 Bn | - | -25,846.86% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -25,846.86% |
| Mar 31, 2026 | -2,602.87% |
| Dec 31, 2025 | -857.59% |
| Jun 30, 2025 | -11,203.10% |
| Mar 31, 2025 | -1,089.48% |
| Mar 31, 2024 | -889.06% |
| Sep 30, 2023 | -286.54% |
| Jun 30, 2023 | -87,996.64% |
| Mar 31, 2023 | -44,238.94% |
| Dec 31, 2022 | -28,333.99% |
| Sep 30, 2022 | -24,668.31% |
| Jun 30, 2022 | -21,056.16% |
| Mar 31, 2022 | -14,736.52% |
| Dec 31, 2021 | -11,761.73% |
| Sep 30, 2021 | -9,005.71% |
| Jun 30, 2021 | -22,822.27% |
| Mar 31, 2021 | -4,357.77% |
API Access
Relay Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=RLAY&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "RLAY", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=RLAY&period=max&api_key=YOUR_API_KEY");
const data = await res.json();